CN113024530A - 一种靛红-1,2,4-噁二唑类化合物及其制备方法和用途 - Google Patents
一种靛红-1,2,4-噁二唑类化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN113024530A CN113024530A CN202110274885.4A CN202110274885A CN113024530A CN 113024530 A CN113024530 A CN 113024530A CN 202110274885 A CN202110274885 A CN 202110274885A CN 113024530 A CN113024530 A CN 113024530A
- Authority
- CN
- China
- Prior art keywords
- isatin
- product
- preparation
- compound
- flask
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
技术领域
背景技术
炎症过程是所有哺乳动物免疫防御的重要组成部分。急性炎症是对人体造成的伤害,可能与病原体的入侵有关,因此需要提前准备防御措施。炎症是由活化的专门细胞(如粒细胞和肥大细胞)活化引起的,这些细胞遍布全身,主要识别宿主细胞中不存在而在微生物中存在的结构,从而触发多种反应,包括通过高毒性非特异性介质(例如活性氧)直接杀死病原体的细胞效应子。此类攻击还会对健康的宿主细胞造成损害,需要严格控制。这种控制是通过流入适应性免疫系统的细胞来实现的,这些细胞产生特定的抗病原体应答,并通过调节(抑制)几种不同类型的细胞从而达到对先天和适应性免疫应答调节的目的。这些调节也可以在病原体消除后终止免疫反应。如果无法消除病原体,或者无法适当调节免疫反应,那么与感染相关的大多数症状的免疫病理也可能持续存在,这种持续性免疫反应的后果可能很严重。随着哺乳动物的衰老,维持适当的免疫稳态所需的复杂调节回路可能会受到损害,结果是免疫控制失衡,倾向于先天应答。在人类中,这表现为一种特征,即存在比年轻人中常见的更高水平的全身性炎症标记物,其中一些与有害健康结果有关。
巨噬细胞在炎症过程中起关键作用。它们在非特异性防御(先天免疫)中起作用,并有助于启动特异性防御机制(适应性免疫)。巨噬细胞负责抗原的识别和加工,以及将外源抗原呈递给抗原特异性T细胞并清除死细胞。在脂多糖(LPS)刺激后,巨噬细胞中激活了主要的细胞内信号传导途径:MyD88依赖性途径。MyD88依赖性途径的激活导致两条不同的下游信号传导途径的激活:转录因子NF-κB途径和MAPK途径。这两个途径诱导协调宿主的炎症反应的多种炎症介质的表达和释放。
Isatin(2,3-dioxindole)是在大多数植物中发现的天然化合物,是一类重要的杂环化合物。Isatin衍生物是合成中重要的底物,可用于合成多种杂环化合物,并用作药物合成的原料。近年来,由于其强大的生物学和药理活性,靛红衍生物已在有机和药物化学领域占有重要地位。由于存在同时含有酮基和内酰胺基团的生物活性吲哚部分,Isatin及其衍生物具有多种生物学特性,例如抗肿瘤、抗菌、消炎、镇痛、抗分枝杆菌、抗惊厥、抗病毒、驱虫、抗HIV、抗氧化剂、中枢神经系统抑制活性等。靛红还显示酶抑制活性和作为消灭肿瘤细胞细胞的毒性剂。此外,Isatin衍生的化合物在大脑中对多种类型的感染具有多种作用,它也显示出抗增殖和半胱天冬酶抑制剂活性。
二唑是一个五元含氮和含氧杂环,其已被普遍用作核心骨架以产生各种新的治疗分子。其中,1,2,4-二唑由于其重要的生物学活性,例如抗病毒、杀菌、除草、镇痛和抗炎,因此引起了广泛关注。二唑在药物研究中通常被认为是酯和酰胺的生物等排体,在药物研发中心它们也已被用作二肽类似物,表现出高效低毒的效果。同时,据研究推测可以利用细胞中的氨基酸转运系统将二唑核传递至靶细胞以实现药物活性。通常,1,2,4-二唑的生物活性归因于其作为酯或酰胺官能团的生物电子等排体取代,杂环骨架对水解反应进行的抗性以及因此而带来的在室温下不同pH水介质中的稳定性。此外,引入氨基会增加相应的二唑衍生物的氢键结合能力和/或改变其电性,从而提升与生物系统作用时的分子识别能力。
发明内容
本发明旨在提供一种靛红-1,2,4-二唑类化合物及其制备方法和用途。本发明依据药物的拼合原理和基于结构的药物分子设计理念,在靛红所具有的靛红分子骨架上引入五元杂环结构,获得了靛红-1,2,4-二唑类衍生物。生物活性测试结果表明本发明靛红-1,2,4-二唑类化合物对小鼠单核巨噬细胞白血病细胞具有良好的抑制活性。
通式中R选自如下基团中的一种:
步骤1:称量靛红2g(8.85mmol)加入50mL圆底烧瓶中并加入磁力转子,再向烧瓶中加入25mL DMF,在冰浴条件下搅拌,再缓慢分批量向烧瓶中加入氢化钠0.36g(15mmol),冰浴搅拌30min后,再量取溴乙酸乙酯1.4mL(13.27mmol)加入烧瓶中,然后升温至75℃加热搅拌反应19h;TLC检测反应完全时,将反应液倒入装有冰水的烧杯中淬灭,然后将析出的产物过滤,将滤液中的产物用乙酸乙酯萃取并浓缩,最后将浓缩后的产物与过滤出来的产物合并即为中间体。
步骤2:将步骤1获得的中间体加入25mL的圆底烧瓶中并加入转子,再向烧瓶中加入甲醇15mL,然后再向烧瓶中加入5%的氢氧化钠溶液17.7mL,60℃下加热搅拌反应6h;TLC检测反应完全时,将反应液倒入装有冰水和搅拌子并放置在磁力搅拌台上的烧杯中,再向烧杯中加入稀盐酸调pH=4,等产物基本析出时用布氏漏斗过滤,干燥(75℃烘箱中烘干)后获得1-乙酸靛红。
步骤3:取苯腈类化合物0.16mL(1.5mmol)加入10mL圆底烧瓶中并加入转子,再称量盐酸羟胺0.13g(1.8mmol)加入烧瓶中,再向烧瓶中加入三乙胺0.32mL(2.3mmol),最后加入5mL甲醇,60℃下加热回流搅拌反应6h;TLC检测反应完全时,将反应液在旋转蒸发仪中旋干,获得粗产物。
所述苯腈类化合物选自苯腈、4-溴苯腈、4-乙基苯腈、胡椒腈、苄腈、4苯氧基苯腈、4-溴丙炔氧基苯腈、4-甲基苯腈、4-三氟甲基苯腈、3-溴苯腈、4-三氟甲氧基苯腈、3-三氟甲基苯腈、间甲基苯腈、4-羟甲基苯腈、4-三氟甲基苯腈、4-苯基苯腈、4-氟苯腈、4-氰基哌啶-1-羧酸叔丁酯、3-苯基苯腈、4-甲氧基苯腈、3-羟基苯腈、3-乙基苯腈、3-氯苯腈、3-碘苯腈、4-碘苯腈、4-溴丙炔氧基苯腈、3-甲氧基苯腈、4-羟基苯腈、4-氯苯腈、3-三氟甲氧基苯腈。
步骤4:向步骤3获得的粗产物中加入1-乙酸靛红0.6g(2mmol)以及CDI 0.25g(1.5mmol),然后再向烧瓶中加入DMF5mL,90℃下加热搅拌反应20h;TLC检测原料已很少时,将反应液用乙酸乙酯在分液漏斗中萃取,柱层析分离,展开剂为PE:EA=3:1,得产物,最后再用精馏级乙酸乙酯进行重结晶,得目标产物。
步骤1中,靛红、溴乙酸乙酯与氰化钠的物质的量之比为1:1.5:1.7。
步骤3中,苯腈、盐酸羟胺与三乙胺的物质的量之比为1:1.2:1.5。
步骤4中,苯肟、1-乙酸靛红与CDI的物质的量之比为1:1.3:1。
附图说明
具体实施方式
以下通过具体的实施例对本发明技术方案作进一步详细说明,但应注意本发明的范围并不受这些实施例的任何限制。
1、称量靛红2g(8.85mmol)加入50mL圆底烧瓶中并加入磁力转子,再向烧瓶中加入25mL DMF,将圆底烧瓶置于冰浴搅拌条件下,再缓慢分批量向烧瓶中加入氢化钠0.36g(15mmol),冰浴搅拌30min后,再量取溴乙酸乙酯1.4mL(13.27mmol)加入烧瓶中,然后将烧瓶放入75℃油浴锅中加热并搅拌19h;TLC检测反应完全时,将反应液倒入装有冰水的烧杯中淬灭,然后将析出的产物过滤,将滤液中的产物用乙酸乙酯萃取并浓缩,最后将浓缩后的产物与过滤出来的产物合并即为下一步的反应物。
2、将步骤1的产物装入25mL的圆底烧瓶中并加入转子,再向烧瓶中加入甲醇15mL,然后再向烧瓶中加入5%的氢氧化钠溶液17.7mL,将烧瓶置于60℃油浴锅中加热并搅拌6h;TLC检测反应完全时,将反应液倒入装有冰水和搅拌子并放置在磁力搅拌台上的烧杯中,再向烧杯中加入稀盐酸调pH至酸性,等产物基本析出时用布氏漏斗过滤,最后将过滤出来的1-乙酸靛红放入75℃烘箱中烘干。
3、取4-溴苯腈0.18mL(1.5mmol)加入10mL圆底烧瓶中并加入转子,再称量盐酸羟胺0.13g(1.8mmol)加入烧瓶中,再向烧瓶中加入三乙胺0.32mL(2.3mmol),最后加入5mL甲醇,将烧瓶置于60℃的油浴锅中并回流搅拌加热6h;TLC检测反应完全时,将反应液在旋转蒸发仪中旋干,粗产物产物作为下一步的原料。
4、向步骤3的已旋干的圆底烧瓶中加入1-乙酸靛红0.6g(2mmol),再加入CDI0.25g(1.5mmol),然后再向烧瓶中加入DMF5mL,将烧瓶置于90℃油浴锅中加热并搅拌20h;TLC检测原料已很少时,将反应液用乙酸乙酯在分液漏斗中萃取,柱层析分离,展开剂为PE:EA=3:1,得产物,最后再用精馏级乙酸乙酯进行重结晶,得终产物。
黄色固体,产率85%。1HNMR(600MHz,CDCl3)δ7.89(d,J=8.1Hz,2H),7.69(d,J=7.2Hz,1H),7.60(t,J=7.7Hz,3H),7.19(t,J=7.3Hz,1H),6.94(d,J=7.7Hz,1H),5.25(d,J=37.2Hz,2H).13CNMR(101MHz,CDCl3)δ181.69,173.09,168.17,157.69,149.35,138.70,132.27,129.05,126.31,125.95,124.86,124.71,117.84,110.38,35.76.MS(ESI)m/z:382.99[M+H]+.
注:该化合物为已报道的化合物,在此仅用于活性参考。
制备方法同实施例1。以乙腈代替4-溴苯腈得黄色固体,产率70%。1HNMR(400MHz,CDCl3)δ7.69(t,J=8.5Hz,1H),7.66(m,1H),7.22(t,J=7.6Hz,1H),6.91(d,J=8.0Hz,1H),5.17(s,2H),2.41(s,3H).13C NMR(101MHz,CDCl3)δ182.22,172.59,167.80,158.02,149.37,138.66,125.88,124.65,124.02,117.81,112.29,110.35,35.65,29.34,27.46,11.56.MS(ESI)m/z:243.06[M+H]+.
制备方法同实施例1,不同的是以4-乙基苯腈代替4-溴苯腈得黄色固体,产率82%。1HNMR(400MHz,CDCl3)δ7.97(d,J=8.2Hz,2H),7.72(d,J=7.2Hz,2H),7.63(t,J=7.8Hz,2H),7.32(d,J=8.1Hz,2H),7.22(t,J=7.5Hz,2H),6.98(d,J=7.9Hz,1H),5.26(s,2H),2.72(q,J=7.6Hz,2H),1.53(m,3H).13CNMR(101MHz,CDCl3)δ181.82,172.62,168.84,157.70,149.46,148.34,138.70,128.48,127.59,125.86,124.62,123.31,117.81,110.52,35.83,28.92,15.33.MS(ESI)m/z:333.11[M+H]+.
制备方法同实施例1,不同的是以苯腈代替4-溴苯腈得黄色固体,产率91%。1HNMR(600MHz,CDCl3)δ8.03(m,2H),7.68(dd,J=7.5,0.8Hz,1H),7.60(td,J=7.8,1.3Hz,1H),7.53(m,2H),7.18(td,J=7.6,0.5Hz,1H),6.95(d,J=8.0Hz,1H),5.23(s,2H).13CNMR(151MHz,CDCl3)δ182.09,172.78,169.12,157.97,149.74,138.62,131.59,128.90,127.52,125.81,124.58,118.21,110.42,35.74.MS(ESI)m/z:305.08[M+H]+.
制备方法同实施例1,不同的是以胡椒腈代替4-溴苯腈得黄色固体,产率83%。1HNMR(600MHz,CDCl3)δ7.68(d,J=7.4Hz,1H),7.59(ddd,J=8.1,6.7,4.1Hz,2H),7.46(d,J=1.5Hz,1H),7.19(t,J=7.5Hz,1H),6.94(d,J=8.0Hz,1H),6.87(d,J=8.1Hz,1H),6.02(d,J=6.7Hz,2H),5.20(s,2H).13CNMR(101MHz,DMSO)δ182.53,174.95,167.89,158.54,150.68,150.14,148.52,138.77,125.18,124.30,122.74,119.76,118.27,111.59,109.48,106.95,102.42,36.16.MS(ESI)m/z:349.07[M+H]+.
制备方法同实施例1,不同的是以苄腈代替4-溴苯腈得黄色固体,产率76%。1HNMR(400MHz,CDCl3)δ7.69(d,J=7.5Hz,1H),7.59(td,J=7.9,1.2Hz,1H),7.36(m,2H),7.28(d,J=6.0Hz,2H),7.21(t,J=7.6Hz,1H),6.88(d,J=8.0Hz,1H),5.15(s,2H),4.08(s,2H).13CNMR(101MHz,CDCl3)δ181.73,172.87,170.04,157.64,149.37,138.61,134.84,128.97,128.79,127.33,125.84,124.61,117.78,110.46,35.75,32.18.MS(ESI)m/z:319.10[M+H]+.
制备方法同实施例1,不同的是以4苯氧基苯腈代替4-溴苯腈得黄色固体,产率85%。1HNMR(600MHz,CDCl3)δ7.99(dd,J=19.7,8.9Hz,2H),7.68(d,J=7.4Hz,1H),7.59(t,J=7.8Hz,1H),7.37(t,J=7.9Hz,2H),7.17(dt,J=11.4,7.5Hz,2H),7.09–6.99(m,4H),6.93(t,J=10.4Hz,1H),5.21(s,2H).13CNMR(101MHz,CDCl3)δ181.77,172.68,168.35,160.61,157.70,155.82,149.43,138.69,130.03,129.38,125.90,124.65,124.37,119.88,118.26,110.47,35.76.MS(ESI)m/z:397.11[M+H]+.
制备方法同实施例1,不同的是以4-溴丙炔氧基苯腈代替4-溴苯腈得黄色固体,产率89%。1HNMR(600MHz,CDCl3)δ7.97(d,J=8.8Hz,2H),7.68(d,J=7.4Hz,1H),7.59(t,J=7.8Hz,1H),7.18(t,J=7.5Hz,1H),7.03(d,J=8.8Hz,2H),6.93(d,J=8.0Hz,1H),5.21(s,2H),4.73(d,J=2.3Hz,2H),2.53(t,J=2.3Hz,1H).13CNMR(101MHz,CDCl3)δ181.81,172.58,168.40,160.07,157.70,149.45,138.70,129.22,125.88,124.64,119.22,117.81,115.24,110.49,55.84,35.76.MS(ESI)m/z:359.09[M+H]+.
制备方法同实施例1,不同的是以4-甲基苯腈代替4-溴苯腈得黄色固体,产率90%。1HNMR(400MHz,CDCl3)δ7.94(d,J=7.9Hz,2H),7.72(d,J=7.4Hz,1H),7.63(t,J=7.7Hz,1H),7.30(d,J=5.0Hz,2H),7.22(t,J=7.5Hz,1H),6.99(t,J=10.2Hz,1H),5.25(s,2H),2.43(s,3H).13CNMR(101MHz,CDCl3)δ182.36,172.60,169.45,158.44,149.45,142.10,138.69,129.66,127.49,125.88,124.63,123.63,118.23,110.49,35.79,21.63.MS(ESI)m/z:319.10[M+H]+.
制备方法同实施例1,不同的是以4-三氟甲基苯腈代替4-溴苯腈得黄色固体,产率78%。1HNMR(400MHz,CDCl3)δ8.19(d,J=8.2Hz,2H),7.75(t,J=8.7Hz,3H),7.70(m,1H),7.24(t,J=7.6Hz,1H),6.99(t,J=9.8Hz,1H),5.29(s,2H)..13CNMR(101MHz,CDCl3)δ181.65,173.40,167.86,157.70,149.30,138.72,127.96,125.97,124.76,117.85,110.34,35.74.MS(ESI)m/z:373.07[M+H]+.
制备方法同实施例1,不同的是以3-溴苯腈代替4-溴苯腈得黄色固体,产率82%。1HNMR(400 MHz,CDCl3)δ8.22(t,J=1.7 Hz,1H),8.04(m,1H),7.73(dd,J=7.5,0.8 Hz,1H),7.71–7.59(m,2H),7.37(t,J=7.9 Hz,1H),7.24(td,J=7.6,0.6 Hz,1H),6.97(d,J=8.0 Hz,1H),5.27(s,2H).13CNMR(101 MHz,CDCl3)δ181.67,173.18,168.16,157.83,149.32,138.73,134.64,130.53,127.85,126.03,124.73,123.01,117.84,110.35,35.74.MS(ESI)m/z:382.99[M+H]+.
制备方法同实施例1,不同的是以4-三氟甲氧基苯腈代替4-溴苯腈得黄色固体,产率82%。1HNMR(400 MHz,CDCl3)δ8.14(m,2H),7.73(d,J=7.4 Hz,1H),7.64(t,J=7.4 Hz,1H),7.33(d,J=8.1 Hz,2H),7.23(t,J=7.5 Hz,1H),6.97(d,J=8.0 Hz,1H),5.27(s,2H).13CNMR(101MHz,CDCl3)δ181.71,173.19,167.81,157.71,151.56,149.35,138.73,129.36,125.94,124.72,124.49,121.14,117.82,110.40,35.78.MS(ESI)m/z:389.06[M+H]+.
制备方法同实施例1,不同的是以3-三氟甲基苯腈代替4-溴苯腈得黄色固体,产率84%。1HNMR(400 MHz,CDCl3)δ8.33(s,1H),8.26(d,J=7.8 Hz,1H),7.82(dd,J=15.6,7.8Hz,1H),7.72(t,J=9.2 Hz,1H),7.68(m,2H),7.24(t,J=7.6 Hz,1H),6.98(d,J=8.0 Hz,1H),5.56(m,2H).13CNMR(101 MHz,DMSO)δ182.51,175.83,167.31,158.55,150.10,138.77,128.45,126.81,125.40,124.33,118.30,111.61,36.19.MS(ESI)m/z:373.07[M+H]+.
制备方法同实施例1,不同的是以间甲基苯腈代替4-溴苯腈得黄色固体,产率89%。1HNMR(600MHz,CDCl3)δ7.86(m,2H),7.68(d,J=7.4Hz,1H),7.59(td,J=7.9,1.0Hz,1H),7.37(m,2H),7.18(t,J=7.5Hz,1H),6.94(d,J=8.0Hz,1H),5.22(s,2H),2.39(s,7H).13CNMR(101MHz,CDCl3)δ181.79,172.72,168.95,157.69,149.43,138.76,132.44,128.86,128.08,125.83,124.66,117.82,110.45,35.78,21.34.MS(ESI)m/z:305.08[M+H]+.
制备方法同实施例1,不同的是以4-羟甲基苯腈代替4-溴苯腈得黄色固体,产率80%。1HNMR(400MHz,DMSO)δ7.93(d,J=7.9Hz,2H),7.73(t,J=7.9Hz,1H),7.65(d,J=7.5Hz,1H),7.49(d,J=8.0Hz,2H),7.33(d,J=8.0Hz,1H),7.21(t,J=7.5Hz,1H),5.41(s,2H),5.35(t,J=5.7Hz,1H),4.57(d,J=5.7Hz,2H).13CNMR(101MHz,DMSO)δ182.55,175.14,168.20,158.55,150.16,147.10,138.78,127.41,125.20,124.36,118.29,111.59,62.85,36.19.MS(ESI)m/z:335.09[M+H]+.
制备方法同实施例1,不同的是以4-三氟甲基苯腈代替4-溴苯腈得黄色固体,产率78%。1HNMR(400MHz,CDCl3)δ8.19(d,J=8.2Hz,2H),7.74(dd,J=17.7,8.9Hz,3H),7.69(m,1H),7.24(t,J=7.6Hz,1H),6.98(d,J=7.9Hz,1H),5.29(s,2H).13CNMR(101MHz,CDCl3)δ181.65,173.41,167.86,157.71,149.31,138.72,129.29,127.95,125.96,124.87,117.84,110.35,35.74.MS(ESI)m/z:373.07[M+H]+.
制备方法同实施例1,不同的是以4-苯基苯腈代替4-溴苯腈得黄色固体,产率78%。1HNMR(400MHz,CDCl3)δ8.13(d,J=8.4Hz,2H),7.73(dd,J=7.3,3.5Hz,3H),7.65(dd,J=10.5,3.7Hz,3H),7.49(t,J=7.4Hz,2H),7.42(t,J=7.3Hz,1H),7.23(t,J=7.5Hz,1H),7.00(d,J=7.9Hz,1H),5.59(m,2H).13CNMR(101MHz,CDCl3)δ181.78,172.82,168.66,157.71,149.44,144.41,139.99,138.72,128.97,128.06,127.61,127.17,125.91,124.70,117.83,110.48,35.80,31.99,29.72,29.35,27.23,25.80,22.72,14.16.MS(ESI)m/z:381.11[M+H]+.
制备方法同实施例1,不同的是以4-氟苯腈代替4-溴苯腈得黄色固体,产率81%。1HNMR(600MHz,CDCl3)δ8.05(m,2H),7.68(t,J=9.7Hz,1H),7.60(td,J=7.9,1.1Hz,1H),7.17(dt,J=17.3,8.1Hz,3H),6.94(d,J=8.0Hz,1H),5.22(s,2H).13CNMR(151MHz,CDCl3)δ173.40,168.31,165.85,158.37,149.85,138.59,129.74,125.85,124.61,118.18,116.21,116.06,110.33,35.72.MS(ESI)m/z:323.07[M+H]+.
制备方法同实施例1,不同的是以4-氰基哌啶-1-羧酸叔丁酯代替4-溴苯腈得黄色固体,产率50%。1HNMR(600MHz,CDCl3)δ7.65(t,J=8.5Hz,1H),7.59(t,J=7.8Hz,1H),7.18(t,J=7.6Hz,1H),6.88(d,J=8.0Hz,1H),5.20(d,J=90.4Hz,2H),4.21(m,2H),2.99(m,3H),2.02(s,2H),1.96(m,2H),1.72(m,9H),1.43(s,25H).13CNMR(101MHz,CDCl3)δ182.41,167.28,158.05,150.22,138.49,125.69,124.27,117.67,110.08,52.96,41.13.MS(ESI)m/z:412.17[M+H]+.
制备方法同实施例1,不同的是以3-苯基苯腈代替4-溴苯腈得黄色固体,产率67%。1HNMR(400MHz,CDCl3)δ8.29(t,J=1.7Hz,1H),8.04(d,J=7.8Hz,1H),7.79(m,2H),7.70(m,4H),7.50(dd,J=10.3,4.8Hz,2H),7.45(m,1H),7.23(t,J=7.6Hz,1H),6.98(d,J=8.0Hz,1H),5.29(s,2H).13CNMR(101MHz,CDCl3)δ181.78,172.89,168.85,157.70,149.41,142.05,140.04,138.73,130.35,129.45,128.94,127.87,127.20,126.44,126.33,126.25,125.92,124.68,117.83,110.43,35.79.MS(ESI)m/z:381.11[M+H]+.
制备方法同实施例1,不同的是以4-甲氧基苯腈代替4-溴苯腈得黄色固体,产率87%。1HNMR(400MHz,CDCl3)δ8.02–7.95(m,2H),7.72(d,J=7.4Hz,1H),7.63(td,J=7.8,1.3Hz,1H),7.22(t,J=7.7Hz,1H),7.02(m,3H),5.29(d,J=31.8Hz,2H),3.88(s,3H).13CNMR(101MHz,CDCl3)δ182.26,172.47,168.53,162.24,158.71,149.47,138.69,129.22,125.87,124.62,118.37,117.81,114.33,110.49,55.43,35.77.MS(ESI)m/z:335.09[M+H]+.
制备方法同实施例1,不同的是以3-羟基苯腈代替4-溴苯腈得黄色固体,产率71%。1HNMR(400MHz,DMSO)δ9.88(s,1H),7.73(td,J=7.8,1.2Hz,1H),7.65(d,J=7.4Hz,1H),7.36(ddd,J=22.3,14.9,7.7Hz,4H),7.21(t,J=7.5Hz,1H),6.96(ddd,J=8.0,2.4,1.1Hz,1H),5.40(s,2H).13CNMR(101MHz,DMSO)δ182.55,175.11,168.23,158.54,158.33,150.15,138.77,131.50,127.18,125.19,118.27,114.28,112.05,36.16.MS(ESI)m/z:321.07[M+H]+.
制备方法同实施例1,不同的是以3-乙基苯腈代替4-溴苯腈得黄色固体,产率85%。1HNMR(400MHz,CDCl3)δ7.90(m,2H),7.71(dd,J=7.5,0.9Hz,1H),7.63(td,J=7.8,1.3Hz,1H),7.44(m,2H),7.21(dd,J=11.2,3.9Hz,1H),6.98(d,J=8.0Hz,1H),5.29(d,J=22.7Hz,2H),2.72(q,J=7.6Hz,2H),1.49(m,3H).13CNMR(101MHz,CDCl3)δ181.80,172.73,169.00,157.70,149.43,145.15,138.71,131.32,128.96,126.97,125.86,124.95,124.64,117.81,110.47,35.79,28.75,15.53.MS(ESI)m/z:333.11[M+H]+.
制备方法同实施例1,不同的是以3-氯苯腈代替4-溴苯腈得黄色固体,产率80%。1HNMR(400MHz,CDCl3)δ8.05(d,J=1.7Hz,1H),7.95(d,J=7.7Hz,1H),7.73(d,J=7.4Hz,1H),7.65(t,J=7.8Hz,1H),7.54(m,1H),7.43(t,J=7.9Hz,1H),7.24(t,J=7.6Hz,1H),6.98(d,J=8.0Hz,1H),5.27(s,2H).13CNMR(101MHz,CDCl3)δ181.68,173.18,167.87,167.28,157.69,149.33,138.74,138.49,135.04,131.71,130.30,127.64,125.96,125.66,124.73,124.27,117.83,110.37,110.08,52.96,41.13,35.73.MS(ESI)m/z:339.04[M+H]+.
制备方法同实施例1,不同的是以3-碘苯腈代替4-溴苯腈得黄色固体,产率74%。1HNMR(400MHz,CDCl3)δ8.40(d,J=1.2Hz,1H),8.02(d,J=7.8Hz,1H),7.86(d,J=7.9Hz,1H),7.72(d,J=7.5Hz,1H),7.64(td,J=7.9,1.0Hz,1H),7.26–7.19(m,2H),6.97(d,J=8.0Hz,1H),5.26(d,J=1.1Hz,2H).13CNMR(101MHz,CDCl3)δ181.67,173.15,167.57,157.68,149.32,140.55,138.73,136.29,130.59,127.84,126.67,125.97,124.73,117.84,110.34,94.38,35.74.MS(ESI)m/z:430.98[M+H]+.
制备方法同实施例1,不同的是以4-碘苯腈代替4-溴苯腈得黄色固体,产率77%。1HNMR(400MHz,CDCl3)δ7.85(d,J=8.5Hz,2H),7.78(d,J=8.6Hz,2H),7.73(d,J=7.4Hz,1H),7.64(td,J=7.9,1.1Hz,1H),7.23(t,J=7.5Hz,1H),6.97(d,J=8.0Hz,1H),5.26(s,2H).13CNMR(101MHz,CDCl3)δ182.30,173.07(s),168.32,157.68,149.34,138.71,138.22,129.01,125.95,125.41,124.71,117.83,110.38,98.52,35.73.MS(ESI)m/z:430.98[M+H]+.
制备方法同实施例1,不同的是以4-溴丙炔氧基苯腈代替4-溴苯腈得黄色固体,产率80%。1HNMR(400MHz,CDCl3)δ7.77(m,4H),7.42(t,J=8.0Hz,1H),7.21(dd,J=16.0,8.5Hz,1H),7.15(dd,J=8.2,2.1Hz,1H),6.98(d,J=8.0Hz,1H),5.26(s,2H),4.77(d,J=2.3Hz,2H),2.66(m,1H).13CNMR(101MHz,CDCl3)δ181.76,172.86,168.62,157.75,149.40,138.71,130.18,127.19,125.91,124.67,120.87,118.67,117.82,113.48,110.47,56.00,35.76.MS(ESI)m/z:359.09[M+H]+.
制备方法同实施例1,不同的是以3-甲氧基苯腈代替4-溴苯腈得黄色固体,产率89%。1HNMR(400MHz,CDCl3)δ7.72(d,J=7.5Hz,1H),7.68(m,2H),7.57(dd,J=2.5,1.3Hz,1H),7.40(t,J=8.0Hz,1H),7.22(t,J=7.6Hz,1H),7.10(m,1H),6.98(d,J=8.0Hz,1H),5.26(s,2H),3.88(s,3H).13CNMR(151MHz,CDCl3)δ182.25,172.77(s),169.24,159.87,158.28,149.38,138.63,130.04,127.08,125.81,124.59,119.97,117.96,117.80,112.19,110.41,55.45,35.73.MS(ESI)m/z:335.09[M+H]+.
制备方法同实施例1,不同的是以4-羟基苯腈代替4-溴苯腈得黄色固体,产率78%。1HNMR(600MHz,DMSO)δ10.10(s,2H),7.76(d,J=8.6Hz,4H),7.68(t,J=7.8Hz,2H),7.61(d,J=7.4Hz,2H),7.27(d,J=8.0Hz,2H),7.17(t,J=7.5Hz,2H),6.86(d,J=8.6Hz,4H),5.33(s,5H).13CNMR(151MHz,CDCl3)δ172.64,168.60,166.07,164.57,159.13,138.23,135.37,134.69,129.82,129.76,126.77,125.72,121.35,116.08,115.93,33.59.MS(ESI)m/z:321.07[M+H]+.
制备方法同实施例1,不同的是以4-氯苯腈代替4-溴苯腈得黄色固体,产率83%。1HNMR(400MHz,CDCl3)δ8.04(m,2H),7.77(m,1H),7.64(td,J=7.8,1.1Hz,1H),7.51(m,2H),7.23(t,J=7.6Hz,1H),6.97(d,J=8.0Hz,1H),5.26(s,2H).13CNMR(101MHz,CDCl3)δ181.71,173.07,168.06,157.69,149.36,138.71,137.86,129.30,128.87,125.94,124.70,124.41,117.82,110.39,35.73.MS(ESI)m/z:339.04[M+H]+.
制备方法同实施例1,不同的是以3-三氟甲氧基苯腈代替4-溴苯腈得黄色固体,产率79%。1HNMR(400MHz,CDCl3)δ7.99(d,J=7.8Hz,1H),7.90(s,1H),7.70(t,J=8.2Hz,1H),7.64(t,J=7.7Hz,1H),7.52(t,J=8.0Hz,1H),7.38(d,J=8.2Hz,1H),7.22(t,J=7.5Hz,1H),6.99(d,J=7.9Hz,1H),5.28(s,2H).13CNMR(101MHz,CDCl3)δ181.72,173.36,167.77,157.72,149.53,149.33,138.77,130.57,127.90,125.89,124.72,123.98,121.66,120.12,119.09,117.80,110.43,35.74.MS(ESI)m/z:389.06[M+H]+.
以LPS刺激诱导RAW264.7的方法得到炎症细胞的模型,分别检测目标化合物对NO、IL-6释放的抑制能力,实验分为三组,分别为空白对照组、加药组、LPS诱导组,采用Griess/Elisa试剂盒检测并且计算D1-D31化合物对RAW 264.7细胞分泌NO、TNF-α和IL-6的抑制率。炎症因子抑制率%=(LPS刺激组-化合物处理组)/(LPS刺激组-空白对照组)×100%。
将从液氮罐中取出的RAW264.7细胞株进行复苏后,转移至培养瓶中,加入DMEM培养基,随后放入细胞培养箱(37℃,5%CO2)中进行培养至对数期,经胰蛋白酶消化用完全培养基进行稀释,按照7×10 4个/孔的标准将细胞接种在24孔板中,继续培养24h。加药组加入含有目标化合物的培养基500μL;其余两组实验组加入等量的新鲜培养基,三组培养1h后,分别给与LPS组和加药组1μL的LPS试剂进行刺激,空白对照组不给与LPS刺激。干预24h后,收集各个孔的上清液,用培养基进行稀释,浓度分别为0,1,2,5,10,20,40,60,100mM;随后每个孔中分别加入20μL标准品和化合物样品;随后向每个孔中先后加入Griess/Elisa试剂,将孔板震荡,待每个孔中的反应液完全混匀后,测定每个孔的OD值。计算炎症因子抑制率。
Claims (9)
步骤1:称量靛红加入圆底烧瓶中,再加入DMF,在冰浴条件下搅拌,缓慢分批量向烧瓶中加入氢化钠,冰浴搅拌30min后,再量取溴乙酸乙酯加入烧瓶中,然后升温至75℃加热搅拌反应19h;TLC监测反应进程,将反应液倒入装有冰水的烧杯中淬灭,然后将析出的产物过滤,将滤液中的产物用乙酸乙酯萃取并浓缩,最后将浓缩后的产物与过滤出来的产物合并即为中间体;
步骤2:将步骤1获得的中间体加入圆底烧瓶中并加入转子,再向烧瓶中加入甲醇以及5%的氢氧化钠溶液,60℃下加热搅拌反应6h;TLC监测反应进程,将反应液倒入装有冰水和搅拌子并放置在磁力搅拌台上的烧杯中,再向烧杯中加入稀盐酸调pH=4,等产物基本析出时用布氏漏斗过滤,干燥后获得1-乙酸靛红;
步骤3:取苯腈类化合物加入圆底烧瓶中,再依次加入盐酸羟胺、三乙胺和甲醇,60℃下加热回流搅拌反应6h;TLC监测反应进程,将反应液在旋转蒸发仪中旋干,获得粗产物;
步骤4:向步骤3获得的粗产物中加入1-乙酸靛红以及CDI,然后再向烧瓶中加入DMF,90℃下加热搅拌反应20h;TLC监测反应进程,将反应液用乙酸乙酯在分液漏斗中萃取,柱层析分离得产物,最后再用精馏级乙酸乙酯进行重结晶,得目标产物。
4.根据权利要求3所述的制备方法,其特征在于:
步骤1中,靛红、溴乙酸乙酯与氰化钠的物质的量之比为1:1.5:1.7。
5.根据权利要求3所述的制备方法,其特征在于:
步骤3中,所述苯腈类化合物选自苯腈、4-溴苯腈、4-乙基苯腈、胡椒腈、苄腈、4苯氧基苯腈、4-溴丙炔氧基苯腈、4-甲基苯腈、4-三氟甲基苯腈、3-溴苯腈、4-三氟甲氧基苯腈、3-三氟甲基苯腈、间甲基苯腈、4-羟甲基苯腈、4-三氟甲基苯腈、4-苯基苯腈、4-氟苯腈、4-氰基哌啶-1-羧酸叔丁酯、3-苯基苯腈、4-甲氧基苯腈、3-羟基苯腈、3-乙基苯腈、3-氯苯腈、3-碘苯腈、4-碘苯腈、4-溴丙炔氧基苯腈、3-甲氧基苯腈、4-羟基苯腈、4-氯苯腈、3-三氟甲氧基苯腈。
6.根据权利要求3或5所述的制备方法,其特征在于:
步骤3中,苯腈类化合物、盐酸羟胺与三乙胺的物质的量之比为1:1.2:1.5。
7.根据权利要求3所述的制备方法,其特征在于:
步骤4中,苯肟、1-乙酸靛红与CDI的物质的量之比为1:1.3:1。
9.根据权利要求8所述的用途,其特征在于:
所述抗炎药物对小鼠单核巨噬细胞白血病细胞在LPS诱导下所产生的炎症具有良好的抑制活性。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110274885.4A CN113024530B (zh) | 2021-03-15 | 2021-03-15 | 一种靛红-1,2,4-噁二唑类化合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110274885.4A CN113024530B (zh) | 2021-03-15 | 2021-03-15 | 一种靛红-1,2,4-噁二唑类化合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113024530A true CN113024530A (zh) | 2021-06-25 |
CN113024530B CN113024530B (zh) | 2023-07-18 |
Family
ID=76469173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110274885.4A Active CN113024530B (zh) | 2021-03-15 | 2021-03-15 | 一种靛红-1,2,4-噁二唑类化合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113024530B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005202122A1 (en) * | 1999-12-21 | 2005-06-30 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
CN106977508A (zh) * | 2017-05-05 | 2017-07-25 | 遵义医学院 | 具有靛红结构的吡唑衍生物用于防治肿瘤的药物及其制法 |
WO2019126568A1 (en) * | 2017-12-22 | 2019-06-27 | Asellus Therapeutics, L.L.C. | Nifuroxazide analogs and therapeutic uses thereof |
CN110734391A (zh) * | 2018-07-02 | 2020-01-31 | 山东大学 | 2,3-二酮吲哚类化合物及其制备方法与应用 |
-
2021
- 2021-03-15 CN CN202110274885.4A patent/CN113024530B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005202122A1 (en) * | 1999-12-21 | 2005-06-30 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
CN106977508A (zh) * | 2017-05-05 | 2017-07-25 | 遵义医学院 | 具有靛红结构的吡唑衍生物用于防治肿瘤的药物及其制法 |
WO2019126568A1 (en) * | 2017-12-22 | 2019-06-27 | Asellus Therapeutics, L.L.C. | Nifuroxazide analogs and therapeutic uses thereof |
CN110734391A (zh) * | 2018-07-02 | 2020-01-31 | 山东大学 | 2,3-二酮吲哚类化合物及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
SHENGPING YU,ET AL.: "Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 27, pages 3319 - 3327, XP085742157, DOI: 10.1016/j.bmc.2019.06.009 * |
Also Published As
Publication number | Publication date |
---|---|
CN113024530B (zh) | 2023-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101887599B1 (ko) | 칼슘 방출-활성화 칼슘 통로의 조정제로서의 피라졸 유도체 | |
RU2360902C2 (ru) | Аллостерические модуляторы метаботропных глутаматных рецепторов | |
JP3519062B2 (ja) | ムスカリン作用物質 | |
DE60221098T2 (de) | Kondensierte heterocyclische derivate | |
JP2002542245A (ja) | 置換イミダゾール、それらの製造および使用 | |
CS228506B2 (en) | Method for the production of optical active ester of 1,4-dihydropyridincarboxyl acid | |
CZ20023931A3 (cs) | Inhibitory HMG-CoA reduktázy a způsob jejich použití | |
CN101627029A (zh) | 作为gpr119活性调节剂的化合物和组合物 | |
CA2188908A1 (en) | Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients | |
US10717727B2 (en) | Pyridinium compounds | |
CN101679255A (zh) | 用于炎症治疗的哌啶酮类 | |
JP2012520246A (ja) | Kcnq2/3モジュレータとしての置換された3−アミノイソオキサゾロピリジン | |
CN112062759A (zh) | 含乙砜基吡啶联1,2,4-噁二唑取代苯甲酰胺类化合物及其制备方法和应用 | |
EP1534687A1 (en) | Pyrimidine compounds | |
CN108314679B (zh) | 一种含1,3,4-噁二唑环二苯乙烯酰胺杀菌剂及其制备方法和应用 | |
JP2002529463A (ja) | 化合物 | |
CN113024530B (zh) | 一种靛红-1,2,4-噁二唑类化合物及其制备方法和用途 | |
CN113429398A (zh) | 一类苯乙酮肟酯咪唑衍生物及其制备方法和应用 | |
Abbady et al. | Synthesis and biological activity of some new pyridines, pyrans, and indazoles containing pyrazolone moiety | |
KR20150103751A (ko) | Crac 채널 억제제로서의 피라졸릴계 카복스아미드 i | |
KR20050034710A (ko) | Mch1 안타고니스트로서의 2차 아미노 아닐린계피페리딘 및 이의 용도 | |
KR20210108555A (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
AU2011297937B2 (en) | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators | |
CN109422734B (zh) | Nortopsentin类生物碱衍生物及其制备和在防治病虫害中的应用 | |
CN115703761A (zh) | 作为wwp1抑制剂的化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |